Balyasny Asset Management LLC Novo Cure LTD Transaction History

Balyasny Asset Management LLC

$61.9 Billion
Q2 2025

A detailed history of Balyasny Asset Management LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Balyasny Asset Management LLC holds 2,270,076 shares of NVCR stock, worth $28.9 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

2,270,076

Previous 1,635,151 38.83%

Holding current value

$28.9 Million

Previous $29.1 Million 38.67%

% of portfolio

0.07%

Previous 0.05%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$15.37 - $19.4 $9.76 Million - $12.3 Million	634,925 Added 38.83%	2,270,076 $40.4 Million
Q1 2025 May 15, 2025	BUY	$17.82 - $30.19 $10.1 Million - $17.1 Million	566,288 Added 52.98%	1,635,151 $29.1 Million
Q4 2024 Feb 14, 2025	BUY	$14.54 - $33.41 $3.34 Million - $7.67 Million	229,689 Added 27.37%	1,068,863 $31.9 Million
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $3.81 Million - $5.7 Million	244,176 Added 41.04%	839,174 $13.1 Million
Q2 2024 Aug 14, 2024	BUY	$11.83 - $24.05 $1.98 Million - $4.03 Million	167,719 Added 39.25%	594,998 $10.2 Million
Q1 2024 May 13, 2024	BUY	$12.42 - $17.29 $1.37 Million - $1.91 Million	110,476 Added 34.87%	427,279 $6.68 Million
Q4 2023 Feb 14, 2024	SELL	$11.13 - $15.78 $8.82 Million - $12.5 Million	-792,812 Reduced 71.45%	316,803 $4.73 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $4.05 Million - $10.6 Million	250,509 Added 29.16%	1,109,615 $17.9 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $20.2 Million - $41.3 Million	501,077 Added 139.95%	859,106 $35.7 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $20.2 Million - $42.5 Million	358,029 New	358,029 $21.5 Million
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $2.31 Million - $3.24 Million	-38,373 Reduced 50.51%	37,593 $3.12 Million
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $5 Million - $8.13 Million	66,614 Added 712.3%	75,966 $5.7 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $1.09 Million - $1.82 Million	9,352 New	9,352 $1.09 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $9.04 Million - $14 Million	-80,588 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$58.05 - $111.31 $16.3 Million - $31.2 Million	-280,467 Reduced 77.68%	80,588 $8.97 Million
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $20.7 Million - $26.9 Million	361,055 New	361,055 $21.4 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $1.25 Million - $1.98 Million	-20,236 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $387,959 - $581,020	9,189 Added 83.18%	20,236 $1.28 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $353,062 - $619,957	11,047 New	11,047 $532,000
Q4 2018 Feb 14, 2019	SELL	$28.72 - $52.63 $263,218 - $482,353	-9,165 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$32.0 - $52.4 $293,280 - $480,246	9,165 New	9,165 $480,000
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $576,364 - $929,152	-29,036 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $560,394 - $686,701	29,036 New	29,036 $633,000

Others Institutions Holding NVCR

# of Institutions

284

Shares Held

77.5M

Call Options Held

943K

Put Options Held

155K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.33B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Novo Cure LTD Transaction History